Life Science-Focused Evotec Shares Plunge To 6 Year Lows On Gloomy Annual Forecast
Life Science-Focused Evotec Shares Plunge To 6 Year Lows On Gloomy Annual Forecast
European life science company Evotec SE (NASDAQ:EVO) announced a priority reset to optimize its business to meet evolving market demand and focus on profitable growth in 2024 and beyond.
欧洲生命科学公司Evotec SE（纳斯达克股票代码：EVO）宣布重置优先级，以优化其业务，以满足不断变化的市场需求，并专注于2024年及以后的盈利增长。
The company is focusing on and rightsizing organizations to overcome the challenging market environment and return to sustainable and profitable growth.
该公司正在专注于组织并调整其规模，以克服充满挑战的市场环境，恢复可持续和盈利的增长。
Shared R&D and Just–Evotec Biologics will replace EVT Execute & EVT Innovate segments in a streamlined reporting structure as of Q1 2024.
共享研发和Just—Evotec Biologics将从2024年第一季度起以简化的报告结构取代EVT Execute和EVT Innovate板块。
The priority reset is anticipated to result in an expected annualized EBITDA improvement of greater than 40 million euros.
重置优先权预计将使年化息税折旧摊销前利润增长超过4000万欧元。
2023 revenues increased 4% Y/Y to 781.4 million euros (+6% at constant FX rates).
2023年收入同比增长4％，达到7.814亿欧元（按固定汇率计算增长6％）。
Revenues from Just – -Evotec Biologics are up 111% to 108.4 million euros.
来自Just —-Evotec Biologics的收入增长了111％，达到1.084亿欧元。
Base business excluding Just–Evotec Biologics is down 4%, including approx. (10)% impact as a result of the severe cyber-attack.
不包括Just—Evotec Biologics在内的基础业务下降了4％，其中包括由于严重的网络攻击而造成的大约（10）％的影响。
The company reported adjusted EBITDA at 66.4 million euros versus 101.7 million a year ago, adjusted for one-off effects related to the recovery from the severe cyber-attack of 15.9 million euros.
该公司报告称，调整后的息税折旧摊销前利润为6,640万欧元，去年同期为1.017亿欧元，调整后的息税折旧摊销前利润为1,590万欧元。
The company appointed Christian Wojczewski as the company's new CEO, effective 01 July.
该公司任命克里斯蒂安·沃伊切夫斯基为公司新任首席执行官，自7月1日起生效。
Mario Polywka, who has led Evotec as Interim CEO since 03 January 2024, will retire at the end of June.
自2024年1月3日起领导Evotec担任临时首席执行官的马里奥·波利瓦卡将于6月底退休。
"Evotec's business displayed great resilience in a challenging market environment. Our central focus for 2024 is to protect our strong balance sheet and refocus the company on profitable growth. Through the planned priority reset and measures to rightsize our operational and corporate structure, we are taking the necessary steps to ensure that we continue to work with our partners to shape the medicines that matter for many years to come, "said Mario Polywka, Interim CEO of Evotec
“在充满挑战的市场环境中，Evotec的业务表现出极大的弹性。我们2024年的核心重点是保护我们强劲的资产负债表，并将公司的重点重新放在盈利增长上。Evotec临时首席执行官马里奥·波利瓦卡说：“通过计划中的优先事项重置和调整运营和公司结构的措施，我们正在采取必要措施，确保我们继续与合作伙伴合作，塑造未来许多年的重要药物。”
Guidance: Evotec forecasts 2024 revenue to grow by a double-digit percentage versus 2023.
指导：Evotec预测，与2023年相比，2024年的收入将以两位数的百分比增长。
The company expects a mid-single to low double-digit percentage reduction of unpartnered research and development expenses.
该公司预计，非合作研发费用将减少中等至低的两位数百分比。
Evotec expects 2024 adjusted EBITDA expected to grow by a mid-double-digit percentage.
Evotec预计，2024年调整后的息税折旧摊销前利润预计将以中两位数的百分比增长。
The company said that the new management team will review the mid-term outlook due to changing industry dynamics, associated pressure on margins, and the implementation of the priority reset.
该公司表示，由于行业动态的变化、相关的利润压力以及优先级重置的实施，新的管理团队将审查中期前景。
Evotec plans to update the market on its mid-term forecast with the release of its H1 2024 results in August 2024.
Evotec计划在2024年8月发布其2024年上半年的业绩，从而向市场更新其中期预测。
Price Action: EVO shares are down 31.90% at $5.21 at the last check Wednesday.
价格走势：在周三的最后一次检查中，EVO股价下跌31.90％，至5.21美元。
Photo via Shutterstock
照片来自 Shutterstock